Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 1478 350008
ISSN: 2329-8790
+44 1478 350008
Omnia K El Gebaly, Naglaa M Hassan, Amira H Soliman, Waleed S Mohamed and Hanan E Shafik
Cairo University, Egypt
Scientific Tracks Abstracts: J Hematol Thrombo Dis
Introduction: The relapse of Acute Myeloid Leukemia (AML) is thought to reflect the failure of current therapies to target leukemia stem cells, typically enriched in the CD34/CD38 cell population. Aim: The aim of this study was to determine the prognostic significance of progenitor cell markers CD34/CD38 in AML. Methods: Progenitor cell markers CD34/CD38 expression was determined on bone marrow mononuclear cells of 84 newly diagnosed adult AML patients with 18 age and sex matched controls, using CD38FITC/CD34PE panel of monoclonal antibodies and analyzed by flow cytometry technique. Results: Expression of CD34 and CD38 cell markers was detected in 79.8% and 85.7% of AML patients respectively, and there was a highly significant difference of CD 34 expression among cases and controls (pâ�?¤0.001). No significant correlation was found between both markers and any of the hematological findings, cytogenetic and FLT3 mutation except with peripheral blood blasts (p=0.05 and 0.005, respectively) and FAB subtypes for CD34 (p=0.006). A significant correlation was found between various CD34/CD38 groups and total leucocytic count, hemoglobin, peripheral blood blasts, and FAB subtypes (p=0.05, 0.047, 0.035 and 0.002 respectively). Also, there was no significant association between both markers expressed separately or in combination with response rate, overall survival and progression free survival. Conclusion: Both progenitor cell markers CD34/CD38 expression might be used as susceptible markers providing important clues for future studies in the early detection of resistant AML cases.